All News

"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.

"The incorporation of NGI into the BCR disease state definition necessitates a consensus within the medical community," write Spyridon P. Basourakos, MD, and Jack R. Andrews, MD.

ORIC-944 was initially being evaluated as a monotherapy in the phase 1b trial.

Topline results from the phase 3 ARANOTE trial showed a statistically and clinically significant improvement in rPFS with the addition of darolutamide to ADT vs ADT alone.

All patients have now been enrolled in cohort 6 of the trial, and dosing with ONCT-534 has begun at the dose level of 1200 mg.

“Our findings suggest an impact of living in disadvantaged neighborhoods—which more commonly affects African Americans—on stress-related genetic pathways in the body. We believe this may increase an individual’s risk of aggressive prostate cancer and contribute to prostate cancer disparities by race,” says Kathryn Hughes Barry, PhD, MPH.

All 3 codes for the procedure will become effective on January 1, 2025.

MK-5684/ODM-208 is a selective CYP11A1 inhibitor currently under investigation in the phase 3 OMAHA1 and OMAHA2a trials.

In May 2024, the FDA cleared an investigational new drug application for 225Ac-FL-020.

Earlier this year, the FDA cleared an investigational new drug application for SYNC-T SV-1022.

Overall, the investigators found a median PSA level of 0.02 ng/mL among transgender women with no diagnosis of prostate cancer.

"Using this as an adjunctive test after PSA screening will give physicians more information to help decide if their patient should undergo a prostate biopsy or not,” says M. Eric Hyndman, MD, PhD, FRCSC.

The fast track designation for BNT324/DB-1311 is supported by safety and efficacy data from an ongoing phase 1/2 trial of the ADC in patients with advanced/metastatic solid tumors.

"Looking at data, if you apply IsoPSA in a consistent manner, based on the studies published, you'll see up to a 55% reduction in unnecessary biopsies," says Jason M. Hafron, MD.

Data from SEER showed a median OS of 23.0 months between the years 2000 to 2004 in patients with mHSPC, which increased to 30.0 months in 2015 to 2019.

"There's obviously a huge interest in focal therapy for prostate cancer, largely because we want to try to prevent the overtreatment of prostate cancer and also develop better approaches to deliver high-quality treatment options for patients," says Timothy D. McClure, MD.

“Our trial’s preliminary major finding is that PSCA-directed CAR T cells may be effective against mCRPC," says Saul J. Priceman, PhD.

The negative margin rate was 72.8% with UnfoldAI vs 1.6% with SOC, translating to a 45-fold increase in accurately identifying cancer extent with the AI tool.

"To me, the most compelling outcome is really the quality-of-life outcomes. General quality of life as well as emotional quality of life improved in the intervention group significantly," says Jill M. Hamilton Reeves, PhD, RD, CSO.

"We concluded that to improve cost-effectiveness, prostate cancer screening strategies should focus on reducing false positives and overdiagnosis," says Roman Gulati, MS.

Data from a phase 1 study of KPG-121 were also recently presented at the 2024 ASCO Annual Meeting.

"The main finding from this network meta-analysis is the ranking of the 4 treatment approaches that we considered," says Scott Morgan, MD, MSc, FRCPC.

The study reported a median rPFS of 8.8 months among 23 adult patients with previously treated, progressive mCRPC.

The change was made following the submission of a real-world evidence study showing that 5- to 10-year overall survival following robot-assisted radical prostatectomy was comparable to that of non-robotic radical prostatectomy.

"We hope this study encourages a national acceptance of active surveillance as an effective management strategy for prostate cancer,” says Daniel Lin, MD.

The IND acceptance will initiate the launch of a phase 1 trial to evaluate the safety, tolerability, and preliminary anti-tumor activity of 225Ac-FL-020 in patients with mCRPC.

"A unique aspect of AUA guidelines is the robust methodological review," says Todd M. Morgan, MD.

"Since the phase 2 data of the combination therapy of LAE002 (afuresertib) plus LAE001 demonstrated encouraging anti-tumor activity and safety profile in patients with mCRPC, a following phase 3 pivotal trial design has been discussed with the US FDA and the approval for the protocol has been received this month," said Yong Yue, MD, PhD.

"When thinking about living with prostate cancer, this is really a couples' disease, and partners' unmet needs should be part of the conversation," says Stacy Loeb, MD.

Preliminary results from the CUPID study were based on data from 11 evaluable patients with advanced prostate cancer.